Nanospect (Human Serum Albumin)

Human Serum Albumin adds colloidal protein to the bloodstream, raising plasma oncotic pressure. This gradient draws fluid from the interstitial space into the vascular compartment, expanding blood volume and improving tissue perfusion in patients with fluid deficits.

The dose of Nanospect is individualized. The prescribing clinician determines the amount based on the patient’s weight, clinical condition, and target plasma albumin level, following local guidelines and product labeling.

Safety data for Human Serum Albumin in pregnancy and lactation are limited. Use is generally reserved for situations where the benefit outweighs potential risk, and the decision should be made by the treating physician in consultation with the patient.

To order Nanospect, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Nanospect (human serum albumin) provides oncotic support, unlike crystalloid solutions that act primarily by expanding extracellular fluid. Compared with synthetic colloids, albumin has a well‑characterized safety profile and is less associated with coagulopathy, but it is more costly and requires refrigeration.

Nanospect must be stored at 2‑8 °C, protected from light, and should never be frozen or shaken. Before use, inspect the vial for particulate matter or discoloration and allow the solution to reach room temperature if required for infusion.

Nanospect is administered intravenously or subcutaneously by a qualified healthcare professional. The solution is typically infused slowly, with the rate adjusted according to the patient’s hemodynamic response and clinical protocol.

Serious risks include anaphylaxis, severe allergic reactions, pulmonary edema from volume overload, and thromboembolic events. Prompt recognition of symptoms such as difficulty breathing, sudden swelling, or chest pain is essential, and immediate medical intervention should be initiated.

Nanospect should be avoided in patients with known hypersensitivity to human serum albumin, those with uncontrolled heart failure where volume overload is a concern, and individuals in whom the risk of allergic reaction outweighs the clinical benefit.